Epstein Secrets

sing the Martin-Hopkins calculation, which is a validated novel method providing better accuracy than the Friedewald equation in the estimation of LDL-C. Martin SS et al. JAMA. 2013;310(19): 2061-2068 (http://education.QuestDiagnostics.com/faq/FAQ164) CHOL/HDLC RATIO 9.4 H NON HDL CHOLESTEROL 193 H

with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option. HS CRP 1.1 <5.0 (talc) <130 mg/dL (talc) mg/L The above test was performed; the specimen was lipemic. Average relative cardiovascular risk according

sing the Martin-Hopkins calculation, which is a validated novel method providing better accuracy than the Friedewald equation in the estimation of LDL-C. Martin SS et al. JAMA. 2013;310(19): 2061-2068 (http://education.QuestDiagnostics.com/faq/FAQ164) CHOL/HDLC RATIO 7.3 H NON HDL CHOLESTEROL 184 H

dL 11.0-15.0 % 140-400 Thousand/uL 7.5-12.5 fL 1500-7800 cells/uL 850-3900 cells/uL 200-950 cells/uL 15-500 cells/uL 0-200 cells/uL Lab MI HS CRP PERFORMING SITE: MI QUEST DIAGNOSTICS.MIAMI. HMO COMMERCE PARKWAY. MIRAMAR. FL 33015.3938 Laboratocc Outdo': JULIE I. FRIEDMAN.MD.CLIA. IOD0277334

sing the Martin-Hopkins calculation, which is a validated novel method providing better accuracy than the Friedewald equation in the estimation of LDL-C. Martin SS et al. JAMA. 2013;310(19): 2061-2068 (http://education.QuestDiagnostics.com/faq/FAQ164) CHOL/HDLC RATIO 8.0 H NON HDL CHOLESTEROL 204 H

with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option. HS CRP 1.3 Average relative cardiovascular risk according to AHA/CDC guidelines. For ages >17 hs-CRP mg/L <1.0 1.0-3.0 3.1-10.0 >10.0 Years: Risk

sing the Martin-Hopkins calculation, which is a validated novel method providing better accuracy than the Friedewald equation in the estimation of LDL-C. Martin SS et al. JAMA. 2013;310(19): 2061-2068 (http://education.QuestDiagnostics.com/faq/FAQ164) CHOL/HDLC RATIO 7.6 H NON HDL CHOLESTEROL 190 H

with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option. HS CRP 0.9 Lower relative cardiovascular risk according to AHA/CDC guidelines. For ages >17 hs-CRP mg/L <1.0 1.0-3.0 3.1-10.0 >10.0 Years: Risk A

sing the Martin-Hopkins calculation, which is a validated novel method providing better accuracy than the Friedewald equation in the estimation of LDL-C. Martin SS et al. JAMA. 2013;310(19): 2061-2068 (http://education.QuestDiagnostics.com/faq/FAQ164) CHOL/HDLC RATIO 8.4 H NON HDL CHOLESTEROL 215 H

with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option. HS CRP 1.2 mg/dL (talc) <5.0 (talc) <130 mg/dL (talc) mg/L The above test was performed; the specimen was lipemic. Average relative cardiovascular r

sing the Martin-Hopkins calculation, which is a validated novel method providing better accuracy than the Friedewald equation in the estimation of LDL-C. Martin SS et al. JAMA. 2013;310(19): 2061-2068 (http://education.QuestDiagnostics.com/faq/FAQ164) CHOL/HDLC RATIO 7.4 H NON HDL CHOLESTEROL 179 H

with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option. HS CRP 1.2 Average relative cardiovascular risk according to AHA/CDC guidelines. For ages >17 hs-CRP mg/L <1.0 1.0-3.0 3.1-10.0 >10.0 Years: Risk